Does the media prefer NTRA or MDGL?

In the previous week, Natera had 9 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 19 mentions for Natera and 10 mentions for Madrigal Pharmaceuticals. Natera's average media sentiment score of 1.21 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RVMD or MDGL?

In the previous week, Revolution Medicines had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 13 mentions for Revolution Medicines and 10 mentions for Madrigal Pharmaceuticals. Revolution Medicines' average media sentiment score of 1.20 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDGL or BIIB?

In the previous week, Biogen had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for Biogen and 10 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.10 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSM or MDGL?

In the previous week, Insmed had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for Insmed and 10 mentions for Madrigal Pharmaceuticals. Insmed's average media sentiment score of 1.15 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Madrigal Pharmaceuticals (MDGL) Competitors

$534.49 +1.37 (+0.26%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$534.42 -0.07 (-0.01%)

As of 09/11/2026 07:30 PM Eastern

Compare

MDGL vs. NTRA, RVMD, ALNY, BIIB, and INSM

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? Madrigal Pharmaceuticals's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Natera?

Natera (NASDAQ:NTRA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

99.9% of Natera shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Natera has higher revenue and earnings than Madrigal Pharmaceuticals. Natera is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

In the previous week, Natera had 9 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 19 mentions for Natera and 10 mentions for Madrigal Pharmaceuticals. Natera's average media sentiment score of 1.21 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has a net margin of -7.11% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Natera's return on equity of -11.38% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Natera presently has a consensus price target of $330.83, suggesting a potential upside of 0.58%. Madrigal Pharmaceuticals has a consensus price target of $699.64, suggesting a potential upside of 30.90%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

Summary

Natera beats Madrigal Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Revolution Medicines had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 13 mentions for Revolution Medicines and 10 mentions for Madrigal Pharmaceuticals. Revolution Medicines' average media sentiment score of 1.20 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Madrigal Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market.

Revolution Medicines currently has a consensus target price of $226.17, indicating a potential upside of 10.99%. Madrigal Pharmaceuticals has a consensus target price of $699.64, indicating a potential upside of 30.90%. Given Madrigal Pharmaceuticals' higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Revolution Medicines beats Madrigal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 10 mentions for Madrigal Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals currently has a consensus target price of $699.64, indicating a potential upside of 30.90%. Alnylam Pharmaceuticals has a consensus target price of $376.67, indicating a potential upside of 51.47%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Alnylam Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22

Madrigal Pharmaceuticals has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Madrigal Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Biogen?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Biogen has a net margin of 8.32% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Biogen's return on equity of 11.18% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Biogen	8.32%	11.18%	6.88%

Madrigal Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Madrigal Pharmaceuticals currently has a consensus target price of $699.64, suggesting a potential upside of 30.90%. Biogen has a consensus target price of $230.14, suggesting a potential upside of 5.98%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Biogen had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for Biogen and 10 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.10 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Insmed currently has a consensus target price of $205.52, indicating a potential upside of 58.81%. Madrigal Pharmaceuticals has a consensus target price of $699.64, indicating a potential upside of 30.90%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Insmed has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Insmed's net margin of -76.94%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Madrigal Pharmaceuticals has lower revenue, but higher earnings than Insmed. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	24.84	-$1.28B	-$4.11	N/A
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

In the previous week, Insmed had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for Insmed and 10 mentions for Madrigal Pharmaceuticals. Insmed's average media sentiment score of 1.15 beat Madrigal Pharmaceuticals' score of 0.82 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insmed beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDGL vs. The Competition

Export

Metric	Madrigal Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.32B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-41.47	14.18	274.95	25.29
Price / Sales	12.88	1,477.55	656.56	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	20.14	15.12	10.33	6.20
Net Income	-$288.28M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-1.22%	-4.34%	-3.32%	-2.35%
1 Month Performance	-0.32%	-0.02%	-0.41%	-2.77%
1 Year Performance	23.66%	40.64%	19.21%	7.63%

Madrigal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDGL Madrigal Pharmaceuticals	3.2807 of 5 stars	$534.49 +0.3%	$699.64 +30.9%	+21.6%	$12.32B	$958.40M	N/A	915	News Coverage Insider Trade
NTRA Natera	2.1538 of 5 stars	$328.18 flat	$319.38 -2.7%	+89.2%	$47.31B	$2.31B	N/A	6,140	Positive News Analyst Forecast
RVMD Revolution Medicines	2.9753 of 5 stars	$210.02 flat	$200.74 -4.4%	+340.7%	$45.01B	$11.58M	N/A	250	Positive News Analyst Forecast Insider Trade
ALNY Alnylam Pharmaceuticals	4.4566 of 5 stars	$266.11 flat	$386.14 +45.1%	-46.9%	$35.61B	$3.71B	49.46	2,770	Positive News Analyst Forecast
BIIB Biogen	3.2678 of 5 stars	$220.83 flat	$228.50 +3.5%	+45.9%	$32.63B	$9.89B	39.08	7,500	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDGL) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. NTRA, RVMD, ALNY, BIIB, and INSM

How does Madrigal Pharmaceuticals compare to Natera?

Summary

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Summary

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Summary

How does Madrigal Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. NTRA, RVMD, ALNY, BIIB, and INSM

How does Madrigal Pharmaceuticals compare to Natera?

Do insiders & institutionals hold more shares of NTRA or MDGL?

Which has stronger earnings & valuation, NTRA or MDGL?

Does the media prefer NTRA or MDGL?

Is NTRA or MDGL more profitable?

Do analysts prefer NTRA or MDGL?

Which has more risk & volatility, NTRA or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Do insiders & institutionals believe in RVMD or MDGL?

Does the media prefer RVMD or MDGL?

Is RVMD or MDGL more profitable?

Which has higher earnings and valuation, RVMD or MDGL?

Which has more risk and volatility, RVMD or MDGL?

Do analysts recommend RVMD or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do insiders and institutionals have more ownership in MDGL or ALNY?

Does the media refer more to MDGL or ALNY?

Do analysts prefer MDGL or ALNY?

Which has stronger valuation and earnings, MDGL or ALNY?

Which has more volatility and risk, MDGL or ALNY?

Is MDGL or ALNY more profitable?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Is MDGL or BIIB more profitable?

Which has more volatility and risk, MDGL or BIIB?

Do analysts prefer MDGL or BIIB?

Does the media favor MDGL or BIIB?

Do institutionals & insiders have more ownership in MDGL or BIIB?

Which has preferable earnings and valuation, MDGL or BIIB?

Summary

How does Madrigal Pharmaceuticals compare to Insmed?

Do institutionals and insiders have more ownership in INSM or MDGL?

Do analysts rate INSM or MDGL?

Which has more volatility & risk, INSM or MDGL?

Is INSM or MDGL more profitable?

Which has preferable valuation and earnings, INSM or MDGL?

Does the media refer more to INSM or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools